companies innovating obesity treatment glp-1 drugs 2025 Amgen Reshapes the Drug Market with Innovative MariTide Obesity Treatment Pipeline: Patents and

Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus

For patients pursuing serious, sustained weight management who meet clinical criteria

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

Its important to talk with a healthcare provider about how long to use these medicines and make long-term healthy lifestyle changes to help keep weight off for good.What are the side effects?Common side effects include nausea, vomiting, diarrhea, abdominal pain, or constipation

However, renal effects of GLP-1 in heart failure (HF) has not been elucidated